AMP® NT-proBNP Test

• Tweet

Recent research shows that elevated levels of N-terminal prohormone brain natriuretic peptide (NT-proBNP) in plasma are thought to be associated with congestive heart failure (CHF). AMP® NT-proBNP Test from Canadian company Response Biomedical has just been approved in Canada to aid “in the diagnosis and assessment of severity in individuals suspected of having congestive heart failure (CHF) and may aid in the risk stratification of patients with acute coronary syndrome and heart failure.” The test has been available in the EU for a while now, and is awaiting FDA clearance. Below are the references to learn more about the test and the diagnostic accuracy of the measurement of NT-proBNP for CHF.
Abstracts: (1) N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure. Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study.;
(2) N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization.;
(3) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study.;
(4) Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.
Press release: Response Biomedical Receives Approval to Market NT-proBNP Congestive Heart Failure Marker Test in Canada …
Product page: Response Biomedical – Clinical Products …